Table 1. Numbers of mice used in the study at each time point.
| Week | PC | TV Ad35+ | TV Ad26+ | TV Ad26- | NC-V | NC-T4 | NC-IU | NC-UU | Total |
|---|---|---|---|---|---|---|---|---|---|
| -2 | 5 | 5 | |||||||
| 0 | 5 | 5 | |||||||
| 4 | 5 | 5 | 5 | 15 | |||||
| 6 | 5 | 5 | 5 | 5 | 5 | 5 | 30 | ||
| 8 | 5 | 5 | 5 | 5 | 5 | 5 | 30 | ||
| 10 | 5 | 5 | 5 | 5 | 5 | 5 | 30 | ||
| 12 | 8 | 8 | 8 | 8 | 5 | 37 | |||
| 16 | 10 | 10 | 10 | 10 | 40 | ||||
| 18 | 5 | 5 | 10 | ||||||
| 20 | 10 | 10 | 10 | 10 | 40 | ||||
| 24 | 10 | 10 | 10 | 10 | 40 | ||||
| 28 | 23 | 23 | 23 | 23 | 23 | 115 | |||
| 36 | 23 | 23 | |||||||
| Total | 81 | 76 | 28 | 28 | 76 | 76 | 35 | 20 | 420 |
420 female BALBc mice were used to obtain data for immunological analysis, relapse CFU measurements and histopathology. Numbers were gradually increased to ensure sufficient power to detect differences between the groups as described previously. NC-UU = negative control, uninfected, untreated; NC-IU = negative control, infected, untreated; PC = positive control, standard therapy; NC-T4 = negative control, shortened therapy; NC-V = negative control, Ad35 empty vector, shortened therapy; TV Ad35+ = Ad35-TBS immunotherapy, shortened therapy; TV Ad26+ = Ad26-TBS immunotherapy, shortened therapy; TV Ad26- = negative control, Ad26 empty vector, shortened therapy.